Independent Strategic Decision Analysis                           

Home Up Info request Sitemap                                                                                                                            

Deal-value                                                                                                       

Home Up

 

Building on the principles of expected NPV (ENPV) calculations, Monte Carlo simulation is an evaluation technique which attempts to model all possible project outcomes subject to uncertainty. It introduces more sophisticated modeling techniques replacing discrete choice decision trees with continuous distributions of possible outcomes. In this way a more representative reflection of possible market events is produced. Monte Carlo simulation also looks to present outcomes as a probability set of all possible outcomes rather than as a probability adjusted average outcome as with ENPV calculations.

When the Monte Carlo simulation approach is applied to licensing agreements the benefits of the use of continuous rather discrete distributions of probabilities and results can be seen. The single inputs for the likelihood of success in research and development trials are replaced by distributions of likely outcomes, modeled from historical results and data. For forecast marketing revenues, single inputs are again replaced by a distribution of likely results, modeling various contingent inputs and again using historical data and trends. The resulting distribution of NPV values for the licensing agreement provides both a likely mean value, as well as the likelihood that the NPV is greater than zero.

By applying a Monte Carlo distribution it can be shown that in agreements valued to have a mean NPV value close to zero, the probability of generating a positive NPV from the licensing agreement based on associated research, development and marketing risks can be as low as 20%. This important information is hidden by the use of expected NPV calculations.

Licensing case study – Monte Carlo simulation

Mean NPV ≈ $0m (using a discount rate of 10%)

Probability NPV>0 ≈ 20% (using a discount rate of 10%)

Where Monte Carlo simulation recognizes the technological and market uncertainties neglected by NPV, real option approaches add the possibility of flexibility, or a flexible response. The staged investments typically made in licensing agreements are valued by assimilating the agreement’s payment structures and risks with common financial options. Since licensing payments and investment decisions are contingent on risky project outcomes, the value of this project management flexibility can be evaluated by looking at the valuation of similar contingent payment structures traded in the investment community.

The most common method applied for the valuation of real options is to replicate payment structures through call and put options. The contingent payments and rewards for a pharmaceutical company are similar to those of the owner of a call option on shares. If when phase III clinical trials are completed the compound has proven to have a positive profile for marketing a pharmaceutical company will continue investments to bring the drug to market, if not it will abandon the compound. Similarly the owner of the share option will exercise his or her right to buy shares at a given price if the share value has risen above the exercise price. In an extension of the framework applied in ENPV and Monte Carlo, real options do not simply calculate the probability of projects failing, they incorporate this into the evaluation as well as the rational decision by a company to abandon subsequent investments on a loss making project.

Licensing case study – Real options evaluation

Real option value = $0.4m (varying the discount rate subject to relative risk)

Based on the illustrated licensing agreement case study, the real options framework incorporates the in-licensers abandonment option in year two to chose not to launch the product if the likely present value of profits less royalty payments falls below the one off $130m manufacturing milestone payment made to the compound originator on product launch. Varying the discount rate appropriately throughout the decision tree to reflect relative risk levels the real options valuation of the licensing contract for the in-licenser is $0.4m, representing a positive investment appraisal. The real options calculation illustrates that when a licensing contract involves contingent payments and management flexibility a positive real options appraisal can be hidden by a negative ENPV.

 

 

 

 

 

 

 

 

Home ] Up ] Innovators ] [ Deal-value ] Deal trends ] Biotechnology ] Modeling ] Integration ]

Send mail to postmaster@delphipharma.com with questions or comments about this web site.
Last modified: September 01, 2005